Trial Profile
Regional Multicenter Study to Evaluate Tolerability and Efficacy of TAF/FTC/RPV Combination (ODEFSEY) in Prevention of Sexual or Blood Exposure to HIV
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 27 Jan 2020
Price :
$35
*
At a glance
- Drugs Emtricitabine/rilpivirine/tenofovir alafenamide (Primary)
- Indications HIV infections
- Focus Adverse reactions; Therapeutic Use
- Acronyms AES ODEFSEY
- 23 Aug 2019 Status changed from not yet recruiting to completed.
- 08 Mar 2018 New trial record